Company Overview and News
Shares listed in China on Friday rallied the most in more than two months after the country’s vice-premier, central bank governor and financial regulatory institutions stepped in to calm investors amid its worst stock rout in about four years.
China’s top financial and regulatory institutions are ramping up support through easier lending for private companies caught in a liquidity squeeze as a result of shares used as collateral for loans.
HONG KONG/BEIJING – China’s top financial officials moved to shore up confidence in the country’s tumbling stock market, a rare show of coordinated verbal support as the government tries to prevent the deepest equity sell-off since 2015 from infecting the world’s second-largest economy.
BEIJING/SHANGHAI (Oct 19): China’s banking regulator said on Friday it plans to start letting funds from products publicly sold by banks’ wealth management subsidiaries be directly invested in shares.
BEIJING: Singapore’s state investment firm, Temasek Holdings Pte, has held talks with Chinese authorities about acquiring a stake in Anbang Insurance Group Co. as well as some of its assets, according to people with knowledge of the matter. Temasek has been examining a potential deal for several months, the people said, asking not to be identified because the discussions are private. The S$308 billion ($224 billion) investment firm isn’t currently in any active negotiations about an Anbang transaction, according to two people with knowledge of its deliberations.
CICHY CHIB 55BC CBQS CICHF CCB CKGOY 0939
In part 2, we discussed how China’s exponential growth has given way to a powerful consumer market that many now want a piece of. But as we are coming to realize, it is not proving to be a simple task. To read the previous section, click here.
GEC GE CHIB SIEGY GNE NYTAB CKGOY
Editor's note: Seeking Alpha is proud to welcome Dilantha De Silva as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more »
The Chinese government legalized peer-to-peer lending platforms in 2015. P2P sites attract money from individual investors – mostly savers – by offering them extraordinarily high yields. They lend this money at high interest rates to borrowers who have trouble getting loans elsewhere – classic subprime. By the end of 2017, there were over 8,000 P2P platforms, according to the People’s Bank of China, with over 50 million registered users.
CCGDF CHIB CKGOY
BEIJING/SHANGHAI (Aug 29): Agricultural Bank of China (AgBank), the country's third-largest lender, expects its asset quality to stabilize in the second half, but said it had increased provisions as trade tensions threaten the global economy.
CICHY CHIB CICHF CCB CKGOY 0939
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...